Clinical trials: Tamsulosin
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS…
- Trial name
- Neptune (NCT01018511)
- Testing
- tamsulosin hydrochloride OCAS 0.4 mg, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
- Where
- 118 sites in Austria, Belarus and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Astellas Pharma Europe B.V.
Prostatic Hyperplasia
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
This study will be an open-label, randomized, single dose, two-period crossover study to determine the bioavailability of a fixed dose combination capsule formulation of dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg)…
- Trial name
- ARI114694 (NCT01254071)
- Testing
- Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
- Where
- Australia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lower Urinary Tract Symptoms
Herbal Supplement Prosta-OK® Neo as an Adjunct Therapy in Patients With Mild to Severe Non-neurogenic Male Lower Urinary Tract Symptoms Receiving Tamsulosin Therapy
The aim of the study is to uses Prosta-OK® Neo that contains herb extracts including lycopene, phellinus linteus, pomegranate, pumpkin seed, selenium and zinc that have been demonstrated with functions of inhibiting 5-alpha…
- Trial name
- NCT04418635
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Acrobio Healthcare Inc.
Prostatic Hyperplasia
A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia
This study is an open-label, randomized, single dose, multi-stage, cross-over study in healthy male subjects of North East Asian ancestry.
- Trial name
- NCT01495026
- Testing
- Dutasteride (0.5mg, fasted state), Dutasteride (0.5mg, fed state), Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the signs and symptoms of benign prostatic hyperplasia…
- Trial name
- NCT02244255
- Testing
- FLOMAX® capsules, Ascending doses of HYTRIN® capsules
- Volunteers
- 1,993 people
- Sponsor
- Boehringer Ingelheim
Bioequivalance
Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x4, replicated, two treatments, four periods, two sequences controlled clinical study
- Trial name
- ACL25-PC006 (NCT07698275)
- Testing
- TAMSULOSIN TEST, OMNIC OCAS REFERENCE
- Where
- Mexico
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- ADIUM
Benign Prostatic Hyperplasia
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers
This study is an open-label, randomized, fasted, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical "Chong Kun Dang Tamsulosin HCl Tablet" and Astellas Phama Korea Inc.
- Trial name
- NCT03887858
- Testing
- Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Adult Males Volunteers
A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State
The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0,4 mg…
- Trial name
- NCT07146711
- Testing
- Tamsulosin (0.4 mg/j), Omnic Ocas®,
- Where
- Armenia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Berlin-Chemie AG Menarini Group
Lower Urinary Tract Symptoms, Prostatic Hyperplasia
A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH
The study will examine the efficacy,safety and tolerability of combination therapy of tamsulosin and solifenacin compared to placebo and monotherapy of tamsulosin and solifenacin in the treatment of males with LUTS associated…
- Trial name
- SATURN (NCT00510406)
- Testing
- tamsulosin hydrochloride, solifenacin succinate
- Where
- 98 sites in Austria, Czechia and 14 more
- Volunteers
- 919 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia
Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design, multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12 weeks in Asian men with signs and…
- Trial name
- NCT00861757
- Testing
- Tadalafil, Tamsulosin
- Where
- 6 sites in Japan, Taiwan
- Volunteers
- 612 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
This will be an open-label, three-period, fixed-sequence study to evaluate the drug-drug interaction, pharmacokinetics and safety of dutasteride and tamsulosin when administered alone and in-combination in Chinese healthy male…
- Trial name
- NCT01957189
- Testing
- Dutasteride and Tamsulosin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Pharmacokinetics
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
The purpose of this study is to evaluate the effect of solifenacin and mirabegron on the concentrations of tamsulosin HCl after combined dosing.
- Conditions
- Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction (DDI)
- Trial name
- NCT02169713
- Testing
- Mirabegron, Solifenacin succinate, Tamsulosin HCl
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Urological Manifestations
Actual Use Study of Tamsulosin in Men
An actual use study to assess how men who respond to advertisements about urinary symptoms use tamsulosin in a simulated Over the Counter (OTC) setting including following "stop use and ask a doctor if" and "ask a doctor before…
- Trial name
- NCT02573311
- Testing
- tamsulosin hydrochloride
- Where
- 40 sites in United States
- Volunteers
- 1,117 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Hyperplasia
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms
Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity in patients with LUTS suggestive of BPH and relevant storage symptoms
- Trial name
- NCT02245490
- Testing
- Tamsulosin HCl controlled release capsules
- Volunteers
- 153 people
- Sponsor
- Boehringer Ingelheim
LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia
The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.
The purpose of this study is to investigate and compare the pharmacokinetic characteristics and safety/tolerability between JLP-1207(Solifenacin/Tamsulosin 5mg/0.2mg)and co-administration of Solifenacin and Tamsulosin between…
- Conditions
- LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02494349
- Testing
- JLP-1207, Solifenacin 5mg+Tamsulosin 0.2mg
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Postoperative Urinary Retention
Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair
Double blinded, randomized controlled prospective study looking at 2 preoperative doses of Tamsulosin an alpha-adrenergic blocker in preventing post-operative urinary retention.
- Trial name
- NCT02958878
- Testing
- Tamsulosin
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Ascension Health
Prostatic Hyperplasia
Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement
Study FDC114615 is a two year, multi-centre, randomised, open-label trial to assess the efficacy of Dutasteride plus tamsulosin when compared to the standard practice of watchful waiting, with a defined escalation to tamsulosin…
- Trial name
- CONDUCT (NCT01294592)
- Testing
- Dutasteride plus tamsulosin, tamsulosin
- Where
- 80 sites in France, Germany and 6 more
- Volunteers
- 742 people
- Sponsor
- GlaxoSmithKline
Healthy
Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers
Study to investigate the effect of CYP3A4 inhibition by ketoconazole on the single oral dose pharmacokinetics of tamsulosin and to investigate the effect on safety and tolerability
- Trial name
- NCT02264171
- Testing
- Tamsulosin HCl, Ketoconazole
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.
Benign prostatic hyperplasia (BPH) is an age-related progressive condition of the prostate gland that results in an increase in prostate size.
- Trial name
- KALLIRROI (NCT06528613)
- Where
- 6 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.